HC Wainwright & Co. Maintains Buy on Arbutus Biopharma, Maintains $6 Price Target
HC Wainwright & Co. analyst Ed Arce maintains Arbutus Biopharma (NASDAQ:ABUS) with a Buy and maintains $6 price target.
Earnings Scheduled For March 2, 2023
Companies Reporting Before The Bell
• argenx (NASDAQ:ARGX) is expected to report quarterly loss at $3.03 per share on revenue of $176.89 million.
Arbutus Biopharma Announces Issuance Of US Patent Related To AB-729
Arbutus Biopharma Corporation (NASDAQ:ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that
Moderna Entangles Pfizer/BioNTech In COVID-19 Vaccine Patent Lawsuits: All You Need To Know
Moderna Inc (NASDAQ: MRNA) has
Arbutus Biopharma Q2 EPS $(0.10) Beats $(0.13) Estimate
Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.13) by 23.08 percent. This is a 56.52 percent increase over losses of $(0.23) per share from
Earnings Scheduled For August 4, 2022
Companies Reporting Before The Bell
• Toyota Motor (NYSE:TM) is projected to report earnings for its first quarter.
Daily Biotech Pulse: Liver Disease-Focused Gene Therapy Pact, Assembly Bio Stops HBV Infection Trial, X4 Pharma Looks For Partners
Here's a roundup of top developments in the biotech space over the last 24 hours:
Arbutus Biopharma Provides Update On The Phase 2A Combination Trial With AB-729 And A Capsid Inhibitor
Arbutus Biopharma Corporation (NASDAQ:ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that
This Analyst Says Arbutus’ EASL Presentations Outline Path For A Functional Cure For Chronic Hepatitis B
JMP Securities reiterates its Market Outperform rating but reduces the price target to $9 from $10 on Arbutus Biopharma Corp (NASDAQ:ABUS) after data…
Arbutus And Vaccitech Dose First Patient In Phase 2a Clinical Trial Combining Therapies For The Treatment Of Chronic Hepatitis B Virus
Arbutus Biopharma Corporation (NASDAQ:ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, and Vaccitech plc